KR20100091994A - 내장 또는 벽측 결손 치료용 재생 생기능성 콜라겐 생매트릭스의 용도 - Google Patents
내장 또는 벽측 결손 치료용 재생 생기능성 콜라겐 생매트릭스의 용도 Download PDFInfo
- Publication number
- KR20100091994A KR20100091994A KR1020107011738A KR20107011738A KR20100091994A KR 20100091994 A KR20100091994 A KR 20100091994A KR 1020107011738 A KR1020107011738 A KR 1020107011738A KR 20107011738 A KR20107011738 A KR 20107011738A KR 20100091994 A KR20100091994 A KR 20100091994A
- Authority
- KR
- South Korea
- Prior art keywords
- biomatrices
- collagen
- collagen foil
- foil
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 578
- 108010035532 Collagen Proteins 0.000 title claims abstract description 578
- 229920001436 collagen Polymers 0.000 title claims abstract description 578
- 230000009278 visceral effect Effects 0.000 title claims abstract description 89
- 230000007547 defect Effects 0.000 title claims abstract description 82
- 230000001172 regenerating effect Effects 0.000 title claims abstract description 11
- 230000001936 parietal effect Effects 0.000 title description 2
- 239000012528 membrane Substances 0.000 claims abstract description 127
- 238000000034 method Methods 0.000 claims abstract description 99
- 108010073385 Fibrin Proteins 0.000 claims abstract description 60
- 102000009123 Fibrin Human genes 0.000 claims abstract description 60
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 60
- 229950003499 fibrin Drugs 0.000 claims abstract description 60
- 239000000565 sealant Substances 0.000 claims abstract description 46
- 238000001356 surgical procedure Methods 0.000 claims abstract description 37
- 239000011888 foil Substances 0.000 claims description 344
- 210000004027 cell Anatomy 0.000 claims description 39
- 230000010261 cell growth Effects 0.000 claims description 37
- 239000000463 material Substances 0.000 claims description 36
- 239000002202 Polyethylene glycol Substances 0.000 claims description 35
- 229920001223 polyethylene glycol Polymers 0.000 claims description 35
- 241000283073 Equus caballus Species 0.000 claims description 28
- 230000015572 biosynthetic process Effects 0.000 claims description 26
- 230000001105 regulatory effect Effects 0.000 claims description 26
- 238000011069 regeneration method Methods 0.000 claims description 24
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 21
- 230000008439 repair process Effects 0.000 claims description 20
- 238000007789 sealing Methods 0.000 claims description 20
- 210000002950 fibroblast Anatomy 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 230000012010 growth Effects 0.000 claims description 14
- 230000002685 pulmonary effect Effects 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 13
- 210000001835 viscera Anatomy 0.000 claims description 13
- 206010016654 Fibrosis Diseases 0.000 claims description 11
- 230000004761 fibrosis Effects 0.000 claims description 11
- 230000000968 intestinal effect Effects 0.000 claims description 11
- 239000003894 surgical glue Substances 0.000 claims description 11
- 230000003834 intracellular effect Effects 0.000 claims description 10
- 241000283690 Bos taurus Species 0.000 claims description 9
- 241001494479 Pecora Species 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 9
- 230000002980 postoperative effect Effects 0.000 claims description 9
- 230000005855 radiation Effects 0.000 claims description 9
- 238000007373 indentation Methods 0.000 claims description 8
- 241000282898 Sus scrofa Species 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 210000002435 tendon Anatomy 0.000 claims description 7
- 230000033228 biological regulation Effects 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 241000288906 Primates Species 0.000 claims description 4
- 241000283984 Rodentia Species 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 210000000936 intestine Anatomy 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 238000002679 ablation Methods 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 abstract description 26
- 238000002271 resection Methods 0.000 abstract description 10
- 230000000181 anti-adherent effect Effects 0.000 abstract description 2
- 230000002085 persistent effect Effects 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 163
- 210000004379 membrane Anatomy 0.000 description 121
- 210000004072 lung Anatomy 0.000 description 116
- 239000010410 layer Substances 0.000 description 77
- 210000004224 pleura Anatomy 0.000 description 50
- 210000003281 pleural cavity Anatomy 0.000 description 27
- 230000008929 regeneration Effects 0.000 description 23
- 210000000779 thoracic wall Anatomy 0.000 description 20
- 238000006703 hydration reaction Methods 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 230000036571 hydration Effects 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 230000000975 bioactive effect Effects 0.000 description 10
- 238000004132 cross linking Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000017423 tissue regeneration Effects 0.000 description 10
- 108010049003 Fibrinogen Proteins 0.000 description 9
- 102000008946 Fibrinogen Human genes 0.000 description 9
- 230000004888 barrier function Effects 0.000 description 9
- 238000002389 environmental scanning electron microscopy Methods 0.000 description 9
- 229940012952 fibrinogen Drugs 0.000 description 9
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 8
- 210000002808 connective tissue Anatomy 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 8
- 108090000190 Thrombin Proteins 0.000 description 7
- 210000001361 achilles tendon Anatomy 0.000 description 7
- 210000000038 chest Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 229960004072 thrombin Drugs 0.000 description 7
- 210000005166 vasculature Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 210000003484 anatomy Anatomy 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 238000009833 condensation Methods 0.000 description 6
- 230000005494 condensation Effects 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000000115 thoracic cavity Anatomy 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000002028 Biomass Substances 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 102000029797 Prion Human genes 0.000 description 4
- 108091000054 Prion Proteins 0.000 description 4
- 239000002262 Schiff base Substances 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- 150000004753 Schiff bases Chemical class 0.000 description 3
- 241000276425 Xiphophorus maculatus Species 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 210000003123 bronchiole Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003601 intercostal effect Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 210000004910 pleural fluid Anatomy 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000036573 scar formation Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 231100001064 visceral defect Toxicity 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical group NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000000876 intercostal muscle Anatomy 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000005033 mesothelial cell Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 201000003144 pneumothorax Diseases 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 229940071643 prefilled syringe Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XDNBGBASBLCTIN-UHFFFAOYSA-L 2-(dimethylamino)ethyl 4-(butylamino)benzoate;n,n-dimethylformamide;n-[2-ethyl-2-(3-methoxyphenyl)butyl]-4-hydroxybutanamide;trimethyl-[4-[[4-(trimethylazaniumyl)cyclohexyl]methyl]cyclohexyl]azanium;diiodide;hydrochloride Chemical compound Cl.[I-].[I-].CN(C)C=O.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1.OCCCC(=O)NCC(CC)(CC)C1=CC=CC(OC)=C1.C1CC([N+](C)(C)C)CCC1CC1CCC([N+](C)(C)C)CC1 XDNBGBASBLCTIN-UHFFFAOYSA-L 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 238000003691 Amadori rearrangement reaction Methods 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010035600 Pleural fibrosis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000005882 aldol condensation reaction Methods 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229940105784 coagulation factor xiii Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical class C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940033618 tisseel Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/044—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98377607P | 2007-10-30 | 2007-10-30 | |
| US60/983,776 | 2007-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20100091994A true KR20100091994A (ko) | 2010-08-19 |
Family
ID=40289337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107011738A Ceased KR20100091994A (ko) | 2007-10-30 | 2008-10-29 | 내장 또는 벽측 결손 치료용 재생 생기능성 콜라겐 생매트릭스의 용도 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8790698B2 (https=) |
| EP (1) | EP2214734B1 (https=) |
| JP (2) | JP2011500237A (https=) |
| KR (1) | KR20100091994A (https=) |
| CN (1) | CN101842122B (https=) |
| AR (1) | AR069109A1 (https=) |
| AU (1) | AU2008317874B2 (https=) |
| CA (1) | CA2703103C (https=) |
| CL (1) | CL2008003219A1 (https=) |
| ES (1) | ES2662647T3 (https=) |
| MX (1) | MX2010004838A (https=) |
| TW (1) | TWI461227B (https=) |
| WO (1) | WO2009056298A2 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101434041B1 (ko) * | 2012-11-08 | 2014-08-29 | 주식회사 제네웰 | 생체조직 유래 소재로부터 제조된 재생 유도용 멤브레인 제조방법 |
| KR101536134B1 (ko) * | 2014-09-26 | 2015-07-14 | 세원셀론텍(주) | 연부조직 수복용 매트릭스의 제조방법 |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6066325A (en) | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
| US8603511B2 (en) | 1996-08-27 | 2013-12-10 | Baxter International, Inc. | Fragmented polymeric compositions and methods for their use |
| US8303981B2 (en) | 1996-08-27 | 2012-11-06 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
| US7435425B2 (en) * | 2001-07-17 | 2008-10-14 | Baxter International, Inc. | Dry hemostatic compositions and methods for their preparation |
| US7927626B2 (en) | 2003-08-07 | 2011-04-19 | Ethicon, Inc. | Process of making flowable hemostatic compositions and devices containing such compositions |
| MX2008014847A (es) * | 2006-05-31 | 2009-04-30 | Baxter Int | Metodo para crecimiento interno en la celula dirigido y regeneracion controlada de los tejidos en la cirugia espinal. |
| TWI436793B (zh) * | 2006-08-02 | 2014-05-11 | 巴克斯特國際公司 | 快速作用之乾密封膠及其使用和製造方法 |
| CA2716872C (en) | 2008-02-29 | 2015-02-10 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
| US9039783B2 (en) * | 2009-05-18 | 2015-05-26 | Baxter International, Inc. | Method for the improvement of mesh implant biocompatibility |
| HRP20150255T1 (hr) * | 2009-06-16 | 2015-05-08 | Baxter International Inc. | Hemostatiäśna spužva |
| US8771258B2 (en) * | 2009-12-16 | 2014-07-08 | Baxter International Inc. | Hemostatic sponge |
| SA111320355B1 (ar) | 2010-04-07 | 2015-01-08 | Baxter Heathcare S A | إسفنجة لايقاف النزف |
| ES2682302T3 (es) | 2010-06-01 | 2018-09-19 | Baxter International Inc | Proceso para la producción de composiciones hemostáticas secas y estables |
| AU2011260260B2 (en) | 2010-06-01 | 2015-09-03 | Baxter Healthcare S.A. | Process for making dry and stable hemostatic compositions |
| JP5973997B2 (ja) | 2010-06-01 | 2016-08-23 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 乾燥した安定な止血用組成物を作製するためのプロセス |
| US8840665B2 (en) | 2010-06-11 | 2014-09-23 | Liventa Bioscience, Inc. | Method of tendon repair with amnion and chorion constructs |
| US20120010727A1 (en) * | 2010-07-06 | 2012-01-12 | AFcell Medical | Amnion and chorion constructs and uses thereof in sport injury surgeries |
| MX346958B (es) | 2011-10-11 | 2017-04-06 | Baxter Int | Composición hemostatica. |
| WO2013053759A2 (en) | 2011-10-11 | 2013-04-18 | Baxter International Inc. | Hemostatic compositions |
| SG11201401878SA (en) | 2011-10-27 | 2014-09-26 | Baxter Int | Hemostatic compositions |
| CN104159527B (zh) | 2012-03-06 | 2017-04-12 | 弗罗桑医疗设备公司 | 包含止血糊剂的压力容器 |
| US8961617B2 (en) | 2012-03-08 | 2015-02-24 | Liventa Bioscience, Inc. | Amnion and chorion constructs and uses thereof in abdominal surgery |
| US20130289724A1 (en) * | 2012-04-25 | 2013-10-31 | AFcell Medical | Amnion and chorion wound dressing and uses thereof |
| RU2636240C2 (ru) | 2012-06-12 | 2017-11-21 | Ферросан Медикал Дивайсиз А/С | Сухая гемостатическая композиция |
| EP2983718A4 (en) | 2013-04-11 | 2016-12-07 | Univ Of Vermont And State Agricultural College | Decellularization and recellularization of whole organs |
| JP6390873B2 (ja) | 2013-06-21 | 2018-09-19 | フェッローサン メディカル ディバイス エー/エス | 減圧膨張させた乾燥組成物およびそれを保持するためのシリンジ |
| BR112016013322B1 (pt) | 2013-12-11 | 2020-07-21 | Ferrosan Medical Devices A/S | métodos para preparação de uma composição seca e para reconstituir uma composição seca, composição seca, uso de uma composição seca, e, kit |
| US11000285B2 (en) * | 2013-12-17 | 2021-05-11 | 3Dt Holdings, Llc | Luminal grafts and methods of making and using the same |
| WO2015095380A1 (en) * | 2013-12-17 | 2015-06-25 | Kassab Ghassan S | Devices, systems and methods for tissue engineering of luminal grafts |
| US9801910B2 (en) * | 2014-03-17 | 2017-10-31 | Ethicon, Inc. | Decellularized pleural matrix |
| KR102703232B1 (ko) | 2014-05-29 | 2024-09-06 | 액세스클로저, 아이엔씨. | 키토산 및 폴리에틸렌 글리콜 공중합체 및 이를 사용하여 혈관 천공을 밀봉하기 위한 방법 및 디바이스 |
| US20170182209A1 (en) * | 2014-06-12 | 2017-06-29 | President And Fellows Of Harvard College | Interpenetrating network hydrogels with independently tunable stiffness |
| BR112017007466B1 (pt) | 2014-10-13 | 2021-03-02 | Ferrosan Medical Devices A/S | método para preparar uma composição seca, método para reconstituir a composição seca, pasta, composição seca, recipiente, kit homeostático, e, uso de uma composição seca |
| US10765705B2 (en) | 2014-11-24 | 2020-09-08 | Prime Merger Sub, Llc | Visco-supplement compositions, and methods of use thereof |
| RU2705905C2 (ru) | 2014-12-24 | 2019-11-12 | Ферросан Медикал Дивайсиз А/С | Шприц для удерживания и смешивания первого и второго веществ |
| CA2986981A1 (en) | 2015-07-03 | 2017-01-12 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
| WO2018067938A1 (en) | 2016-10-06 | 2018-04-12 | The Trustees Of Columbia University In The City Of New York | Cell-seeded porous lung hydrogel sealant |
| US11739291B2 (en) | 2017-04-25 | 2023-08-29 | Purdue Research Foundation | 3-dimensional (3D) tissue-engineered muscle for tissue restoration |
| EP4321182A3 (en) | 2018-05-09 | 2024-05-29 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
| CN110496249B (zh) * | 2018-05-16 | 2022-01-04 | 何浩明 | 血管保护带及其制备方法和应用 |
| US20240077712A1 (en) * | 2019-10-16 | 2024-03-07 | Hitachi High-Tech Corporation | Microscope Slide and Method for Selecting the Same |
| EP4096635A4 (en) | 2020-01-27 | 2024-02-21 | GeniPhys, Inc. | BIOLOGICAL FILLER FOR TISSUE RESTORATION AND REGENERATION |
Family Cites Families (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2507244A (en) | 1947-04-14 | 1950-05-09 | Upjohn Co | Surgical gelatin dusting powder and process for preparing same |
| CH264752A (de) | 1947-06-03 | 1949-10-31 | Hoffmann La Roche | Verfahren zur Herstellung von Trägern für Arzneimittel. |
| SE420565B (sv) | 1974-06-06 | 1981-10-19 | Pharmacia Ab | Hjelpmedel for intravaskuler administraring for anvendning i samband med intravaskuler administrering av en losning eller en suspension av ett diagnostiseringsmedel |
| US4013078A (en) | 1974-11-25 | 1977-03-22 | Feild James Rodney | Intervertebral protector means |
| US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
| DE2843963A1 (de) | 1978-10-09 | 1980-04-24 | Merck Patent Gmbh | Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin |
| US4265233A (en) | 1978-04-12 | 1981-05-05 | Unitika Ltd. | Material for wound healing |
| US4179400A (en) | 1978-05-09 | 1979-12-18 | W. R. Grace & Co. | Process for preparing catalytic solutions of sulfonium salts |
| AT359652B (de) | 1979-02-15 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines gewebekleb- stoffes |
| AT359653B (de) | 1979-02-15 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines gewebekleb- stoffes |
| DE3036033A1 (de) | 1980-09-24 | 1982-05-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Wundbehandlungsmittel in pulverform und verfahren zu seiner herstellung |
| US4300494A (en) | 1979-09-26 | 1981-11-17 | Shell Oil Company | Thermal insulated intake ports |
| US4292972A (en) | 1980-07-09 | 1981-10-06 | E. R. Squibb & Sons, Inc. | Lyophilized hydrocolloio foam |
| DE3105624A1 (de) | 1981-02-16 | 1982-09-02 | Hormon-Chemie München GmbH, 8000 München | Material zum abdichten und heilen von wunden |
| US4424208A (en) | 1982-01-11 | 1984-01-03 | Collagen Corporation | Collagen implant material and method for augmenting soft tissue |
| DE3360633D1 (en) | 1982-02-12 | 1985-10-03 | Unitika Ltd | Anti-cancer device |
| US4482386A (en) | 1982-03-26 | 1984-11-13 | Warner-Lambert Company | Method of conditioning a water swellable hydrocolloid |
| US4543332A (en) | 1982-03-29 | 1985-09-24 | Miles Laboratories, Inc. | Method for the preparation of spherical microorganism cell aggregates |
| US4540410A (en) | 1982-11-16 | 1985-09-10 | Serono Pharmaceutical Partners | Lyophilized compositions, preparation and use thereof |
| EP0132983B2 (en) | 1983-07-14 | 1991-06-12 | Hitachi Chemical Co., Ltd. | Production of gelatin spherical gels and their use |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US4515637A (en) | 1983-11-16 | 1985-05-07 | Seton Company | Collagen-thrombin compositions |
| AT389815B (de) | 1984-03-09 | 1990-02-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten |
| US4600574A (en) | 1984-03-21 | 1986-07-15 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Method of producing a tissue adhesive |
| US4837285A (en) | 1984-03-27 | 1989-06-06 | Medimatrix | Collagen matrix beads for soft tissue repair |
| JPS6144825A (ja) | 1984-08-09 | 1986-03-04 | Unitika Ltd | 止血剤 |
| GB8422950D0 (en) | 1984-09-11 | 1984-10-17 | Warne K J | Hydrogel |
| JPS61122222A (ja) | 1984-11-19 | 1986-06-10 | Koken:Kk | コラ−ゲン又はゼラチンとプロタミンとよりなる止血剤 |
| US5165938A (en) | 1984-11-29 | 1992-11-24 | Regents Of The University Of Minnesota | Wound healing agents derived from platelets |
| US5178883A (en) | 1984-11-29 | 1993-01-12 | Regents Of The University Of Minnesota | Method for promoting hair growth |
| US4600533A (en) | 1984-12-24 | 1986-07-15 | Collagen Corporation | Collagen membranes for medical use |
| US5007916A (en) | 1985-08-22 | 1991-04-16 | Johnson & Johnson Medical, Inc. | Method and material for prevention of surgical adhesions |
| IE59361B1 (en) | 1986-01-24 | 1994-02-09 | Akzo Nv | Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension |
| IL78826A (en) | 1986-05-19 | 1991-05-12 | Yissum Res Dev Co | Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom |
| US5300494A (en) | 1986-06-06 | 1994-04-05 | Union Carbide Chemicals & Plastics Technology Corporation | Delivery systems for quaternary and related compounds |
| US4946870A (en) | 1986-06-06 | 1990-08-07 | Union Carbide Chemicals And Plastics Company Inc. | Delivery systems for pharmaceutical or therapeutic actives |
| US4832686A (en) | 1986-06-24 | 1989-05-23 | Anderson Mark E | Method for administering interleukin-2 |
| US4803075A (en) | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
| US5080893A (en) | 1988-05-31 | 1992-01-14 | University Of Florida | Method for preventing surgical adhesions using a dilute solution of polymer |
| US5017229A (en) | 1990-06-25 | 1991-05-21 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
| US5140016A (en) | 1988-05-31 | 1992-08-18 | University Of Florida | Method and composition for preventing surgical adhesions using a dilute solution of polymer |
| US5350573A (en) | 1988-05-31 | 1994-09-27 | University Of Florida Research Foundation, Inc. | Method and composition for preventing surgical adhesions |
| US5447966A (en) | 1988-07-19 | 1995-09-05 | United States Surgical Corporation | Treating bioabsorbable surgical articles by coating with glycerine, polalkyleneoxide block copolymer and gelatin |
| US5041292A (en) | 1988-08-31 | 1991-08-20 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
| US4925677A (en) | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
| US5135751A (en) | 1988-11-16 | 1992-08-04 | Mediventures Incorporated | Composition for reducing postsurgical adhesions |
| US5126141A (en) | 1988-11-16 | 1992-06-30 | Mediventures Incorporated | Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides |
| US5510418A (en) | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
| US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| US5614587A (en) | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
| US4891359A (en) | 1988-12-08 | 1990-01-02 | Johnson & Johnson Patient Care, Inc. | Hemostatic collagen paste composition |
| DE3903672C1 (https=) * | 1989-02-08 | 1990-02-01 | Lohmann Gmbh & Co Kg | |
| JPH05501814A (ja) | 1989-08-10 | 1993-04-08 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティド | 組織接着剤成分の医療用送り出しシステム |
| US5196185A (en) | 1989-09-11 | 1993-03-23 | Micro-Collagen Pharmaceutics, Ltd. | Collagen-based wound dressing and method for applying same |
| US5061274A (en) | 1989-12-04 | 1991-10-29 | Kensey Nash Corporation | Plug device for sealing openings and method of use |
| US5219328A (en) | 1990-01-03 | 1993-06-15 | Cryolife, Inc. | Fibrin sealant delivery method |
| US5134229A (en) | 1990-01-12 | 1992-07-28 | Johnson & Johnson Medical, Inc. | Process for preparing a neutralized oxidized cellulose product and its method of use |
| JPH0813750B2 (ja) | 1990-03-01 | 1996-02-14 | 持田製薬株式会社 | 経口用トロンビン製剤 |
| US5306501A (en) | 1990-05-01 | 1994-04-26 | Mediventures, Inc. | Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers |
| US5595735A (en) | 1990-05-23 | 1997-01-21 | Johnson & Johnson Medical, Inc. | Hemostatic thrombin paste composition |
| US5209776A (en) | 1990-07-27 | 1993-05-11 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
| US5292362A (en) | 1990-07-27 | 1994-03-08 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
| US5108421A (en) | 1990-10-01 | 1992-04-28 | Quinton Instrument Company | Insertion assembly and method of inserting a vessel plug into the body of a patient |
| US5192300A (en) | 1990-10-01 | 1993-03-09 | Quinton Instrument Company | Insertion assembly and method of inserting a vessel plug into the body of a patient |
| ZA918168B (en) | 1990-10-16 | 1993-04-14 | Takeda Chemical Industries Ltd | Prolonged release preparation and polymers thereof. |
| US5129882A (en) | 1990-12-27 | 1992-07-14 | Novoste Corporation | Wound clotting device and method of using same |
| US5690675A (en) | 1991-02-13 | 1997-11-25 | Fusion Medical Technologies, Inc. | Methods for sealing of staples and other fasteners in tissue |
| CA2089487A1 (en) | 1991-06-14 | 1992-12-15 | Suk-Zu Song | Collagen film drug delivery for proteins |
| AT398079B (de) | 1991-11-04 | 1994-09-26 | Immuno Ag | Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung |
| DE69331096T2 (de) | 1992-02-28 | 2002-08-14 | Cohesion Technologies, Inc. | Injektierbare, keramische verbindungen sowie verfahren zur deren herstellung und anwendung |
| ES2152248T3 (es) | 1992-02-28 | 2001-02-01 | Collagen Corp | Composiciones de colageno de alta concentracion. |
| US5204382A (en) | 1992-02-28 | 1993-04-20 | Collagen Corporation | Injectable ceramic compositions and methods for their preparation and use |
| US5384333A (en) | 1992-03-17 | 1995-01-24 | University Of Miami | Biodegradable injectable drug delivery polymer |
| EP0637226A4 (en) | 1992-04-23 | 1995-06-14 | Scimed Life Systems Inc | DEVICE AND METHOD FOR CLOSING VASCULAR POINTS. |
| IL105529A0 (en) | 1992-05-01 | 1993-08-18 | Amgen Inc | Collagen-containing sponges as drug delivery for proteins |
| AU4406793A (en) | 1992-06-04 | 1993-12-30 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
| US5385606A (en) | 1992-07-06 | 1995-01-31 | Kowanko; Nicholas | Adhesive composition and method |
| US5413571A (en) | 1992-07-16 | 1995-05-09 | Sherwood Medical Company | Device for sealing hemostatic incisions |
| US5428022A (en) | 1992-07-29 | 1995-06-27 | Collagen Corporation | Composition of low type III content human placental collagen |
| US5514379A (en) | 1992-08-07 | 1996-05-07 | The General Hospital Corporation | Hydrogel compositions and methods of use |
| DE4227681C2 (de) * | 1992-08-21 | 1995-05-18 | Becker & Co Naturinwerk | Wundabdeckungsmaterial auf der Basis von Kollagenfasern und Verfahren zu seiner Herstellung |
| WO1994010913A1 (en) | 1992-11-12 | 1994-05-26 | Neville Alleyne | Cardiac protection device |
| US5667839A (en) | 1993-01-28 | 1997-09-16 | Collagen Corporation | Human recombinant collagen in the milk of transgenic animals |
| EP0702959B1 (en) | 1993-05-31 | 2001-08-08 | Kaken Pharmaceutical Co., Ltd. | Cross-linked gelatin gel preparation containing basic fibroblast growth factor |
| FR2715309B1 (fr) | 1994-01-24 | 1996-08-02 | Imedex | Composition adhésive, à usage chirurgical, à base de collagène modifié par coupure oxydative et non réticulé. |
| US5674275A (en) | 1994-04-06 | 1997-10-07 | Graphic Controls Corporation | Polyacrylate and polymethacrylate ester based hydrogel adhesives |
| US5531759A (en) | 1994-04-29 | 1996-07-02 | Kensey Nash Corporation | System for closing a percutaneous puncture formed by a trocar to prevent tissue at the puncture from herniating |
| GB9415739D0 (en) | 1994-07-30 | 1994-09-21 | Scimat Ltd | Gel wound dressing |
| US5516532A (en) | 1994-08-05 | 1996-05-14 | Children's Medical Center Corporation | Injectable non-immunogenic cartilage and bone preparation |
| US5931165A (en) * | 1994-09-06 | 1999-08-03 | Fusion Medical Technologies, Inc. | Films having improved characteristics and methods for their preparation and use |
| US5698213A (en) | 1995-03-06 | 1997-12-16 | Ethicon, Inc. | Hydrogels of absorbable polyoxaesters |
| US5580923A (en) * | 1995-03-14 | 1996-12-03 | Collagen Corporation | Anti-adhesion films and compositions for medical use |
| CA2173508A1 (en) | 1995-03-31 | 1996-10-01 | Tooru Yui | Medical device and method for producing the same |
| JP2905718B2 (ja) * | 1995-03-31 | 1999-06-14 | 東洋紡績株式会社 | 医用材料およびその製造方法 |
| US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
| US6458889B1 (en) | 1995-12-18 | 2002-10-01 | Cohesion Technologies, Inc. | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| WO1997022371A1 (en) | 1995-12-18 | 1997-06-26 | Collagen Corporation | Crosslinked polymer compositions and methods for their use |
| JP3476631B2 (ja) * | 1995-12-21 | 2003-12-10 | 株式会社アムニオテック | ヒト由来の天然コラーゲン膜からなる医用材料 |
| CZ318998A3 (cs) | 1996-04-04 | 1999-09-15 | Baxter Aktiengesellschaft | Hemostatická houba na bázi kolagenu, způsob její přípravy, kryt na ránu a kit k přípravě tohoto krytu |
| US5662598A (en) * | 1996-06-27 | 1997-09-02 | Tobin; Joshua M. | Silicone occlusive dressing for penetrating thoracic trauma |
| US5902832A (en) | 1996-08-20 | 1999-05-11 | Menlo Care, Inc. | Method of synthesizing swollen hydrogel for sphincter augmentation |
| US6066325A (en) | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
| US6063061A (en) | 1996-08-27 | 2000-05-16 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
| US6706690B2 (en) | 1999-06-10 | 2004-03-16 | Baxter Healthcare Corporation | Hemoactive compositions and methods for their manufacture and use |
| US7320962B2 (en) | 1996-08-27 | 2008-01-22 | Baxter International Inc. | Hemoactive compositions and methods for their manufacture and use |
| US7871637B2 (en) * | 1996-08-27 | 2011-01-18 | Baxter International Inc. | Dry hemostatic compositions and methods for their preparation |
| US7435425B2 (en) | 2001-07-17 | 2008-10-14 | Baxter International, Inc. | Dry hemostatic compositions and methods for their preparation |
| TW501934B (en) * | 1996-11-20 | 2002-09-11 | Tapic Int Co Ltd | Collagen material and process for making the same |
| US6458386B1 (en) | 1997-06-03 | 2002-10-01 | Innogenetics N.V. | Medicaments based on polymers composed of methacrylamide-modified gelatin |
| US5908054A (en) | 1997-06-16 | 1999-06-01 | Fusion Medical Technologies, Inc. | Fluid dispersion and delivery assembly and method |
| ATE306935T1 (de) | 1997-09-16 | 2005-11-15 | Integra Lifesciences Corp | Zusammensetzung zur förderung des wachstums von duralem oder meningealem gewebe enthaltend kollagen |
| US5997895A (en) * | 1997-09-16 | 1999-12-07 | Integra Lifesciences Corporation | Dural/meningeal repair product using collagen matrix |
| US6179872B1 (en) * | 1998-03-17 | 2001-01-30 | Tissue Engineering | Biopolymer matt for use in tissue repair and reconstruction |
| US6110484A (en) | 1998-11-24 | 2000-08-29 | Cohesion Technologies, Inc. | Collagen-polymer matrices with differential biodegradability |
| US6328229B1 (en) | 1998-12-18 | 2001-12-11 | Cohesion Technologies, Inc. | Low volume mixing spray head for mixing and dispensing of two reactive fluid components |
| US6312725B1 (en) * | 1999-04-16 | 2001-11-06 | Cohesion Technologies, Inc. | Rapid gelling biocompatible polymer composition |
| US6221109B1 (en) | 1999-09-15 | 2001-04-24 | Ed. Geistlich Söhne AG fur Chemische Industrie | Method of protecting spinal area |
| US6312474B1 (en) * | 1999-09-15 | 2001-11-06 | Bio-Vascular, Inc. | Resorbable implant materials |
| AU9109201A (en) | 2000-09-18 | 2002-03-26 | Organogenesis Inc | Methods for treating a patient using a bioengineered flat sheet graft prostheses |
| JP4104462B2 (ja) | 2001-01-25 | 2008-06-18 | ニコメド ファーマ エイエス | コラーゲンスポンジを調製する方法、コラーゲンフォームの一部を抽出するための装置、および伸長したコラーゲンスポンジ |
| AU2002300450B2 (en) | 2001-08-10 | 2007-04-05 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Collagen Carrier of Therapeutic Genetic Material, and Method |
| US8834864B2 (en) * | 2003-06-05 | 2014-09-16 | Baxter International Inc. | Methods for repairing and regenerating human dura mater |
| MXPA05013119A (es) | 2003-06-05 | 2006-03-17 | Baxter Int | Composiciones para reparar y regenerar duramadre humana. |
| WO2005049105A2 (en) * | 2003-11-10 | 2005-06-02 | Angiotech International Ag | Medical implants and anti-scarring agents |
| CA2536242A1 (en) * | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Implantable sensors and implantable pumps and anti-scarring agents |
| EP1731180B1 (en) * | 2004-03-31 | 2017-10-11 | Nipro Corporation | Antiadhesive kit, process for producing the same and method of adhesion prevention |
| US20080091277A1 (en) * | 2004-08-13 | 2008-04-17 | Kai Deusch | Surgical prosthesis having biodegradable and nonbiodegradable regions |
| US8414907B2 (en) * | 2005-04-28 | 2013-04-09 | Warsaw Orthopedic, Inc. | Coatings on medical implants to guide soft tissue healing |
| WO2006118460A1 (en) | 2005-05-04 | 2006-11-09 | Suprapolix B.V. | Hydrogen bonded hydrogels |
| WO2007001926A2 (en) | 2005-06-24 | 2007-01-04 | Hyperbranch Medical Technology, Inc. | Low-swelling hydrogel sealants for wound repair |
| MX2008014847A (es) | 2006-05-31 | 2009-04-30 | Baxter Int | Metodo para crecimiento interno en la celula dirigido y regeneracion controlada de los tejidos en la cirugia espinal. |
| TWI436793B (zh) | 2006-08-02 | 2014-05-11 | 巴克斯特國際公司 | 快速作用之乾密封膠及其使用和製造方法 |
| US9039783B2 (en) * | 2009-05-18 | 2015-05-26 | Baxter International, Inc. | Method for the improvement of mesh implant biocompatibility |
| HRP20150255T1 (hr) * | 2009-06-16 | 2015-05-08 | Baxter International Inc. | Hemostatiäśna spužva |
-
2008
- 2008-10-29 ES ES08844346.0T patent/ES2662647T3/es active Active
- 2008-10-29 CN CN2008801146855A patent/CN101842122B/zh not_active Expired - Fee Related
- 2008-10-29 CL CL2008003219A patent/CL2008003219A1/es unknown
- 2008-10-29 MX MX2010004838A patent/MX2010004838A/es active IP Right Grant
- 2008-10-29 WO PCT/EP2008/009139 patent/WO2009056298A2/en not_active Ceased
- 2008-10-29 EP EP08844346.0A patent/EP2214734B1/en active Active
- 2008-10-29 KR KR1020107011738A patent/KR20100091994A/ko not_active Ceased
- 2008-10-29 AR ARP080104738A patent/AR069109A1/es unknown
- 2008-10-29 TW TW097141551A patent/TWI461227B/zh not_active IP Right Cessation
- 2008-10-29 JP JP2010530357A patent/JP2011500237A/ja not_active Withdrawn
- 2008-10-29 CA CA2703103A patent/CA2703103C/en active Active
- 2008-10-29 AU AU2008317874A patent/AU2008317874B2/en not_active Ceased
- 2008-10-29 US US12/260,394 patent/US8790698B2/en active Active
-
2014
- 2014-07-28 JP JP2014152844A patent/JP5833717B2/ja not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101434041B1 (ko) * | 2012-11-08 | 2014-08-29 | 주식회사 제네웰 | 생체조직 유래 소재로부터 제조된 재생 유도용 멤브레인 제조방법 |
| KR101536134B1 (ko) * | 2014-09-26 | 2015-07-14 | 세원셀론텍(주) | 연부조직 수복용 매트릭스의 제조방법 |
| WO2016047834A1 (ko) * | 2014-09-26 | 2016-03-31 | 세원셀론텍(주) | 연부조직 수복용 매트릭스 및 그 제조방법 |
| US10973952B2 (en) | 2014-09-26 | 2021-04-13 | Sewoncellontech Co., Ltd. | Matrix for restoring soft tissue and producing method therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008317874A1 (en) | 2009-05-07 |
| US20090142396A1 (en) | 2009-06-04 |
| EP2214734B1 (en) | 2017-12-13 |
| US8790698B2 (en) | 2014-07-29 |
| WO2009056298A3 (en) | 2010-05-20 |
| JP2014198270A (ja) | 2014-10-23 |
| AU2008317874B2 (en) | 2013-12-19 |
| ES2662647T3 (es) | 2018-04-09 |
| CN101842122A (zh) | 2010-09-22 |
| MX2010004838A (es) | 2010-05-21 |
| CN101842122B (zh) | 2013-12-25 |
| JP5833717B2 (ja) | 2015-12-16 |
| JP2011500237A (ja) | 2011-01-06 |
| CA2703103A1 (en) | 2009-05-07 |
| EP2214734A2 (en) | 2010-08-11 |
| CA2703103C (en) | 2017-05-09 |
| WO2009056298A2 (en) | 2009-05-07 |
| CL2008003219A1 (es) | 2009-10-09 |
| AR069109A1 (es) | 2009-12-30 |
| TW200924803A (en) | 2009-06-16 |
| TWI461227B (zh) | 2014-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2703103C (en) | Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects | |
| ES2575933T3 (es) | Colágeno para su uso en la prevención de la formación de fibrosis epidural después de cirugía espinal | |
| US8834864B2 (en) | Methods for repairing and regenerating human dura mater | |
| AU2004245086B2 (en) | Compositions for repairing and regenerating human dura mater | |
| JP4840136B2 (ja) | 癒着防止用キット、癒着防止用キットの製造方法および癒着防止方法 | |
| US20070231372A1 (en) | Tissue Sealant | |
| CN100471529C (zh) | 用于修复和再生人硬膜的组合物 | |
| HK1128638B (en) | Collagen for use in prevention of peridural fibrosis formation after spinal surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20100528 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| AMND | Amendment | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20131029 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20150224 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20150623 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20150224 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20150723 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20150623 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Appeal identifier: 2015101004182 Request date: 20150723 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20150723 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20150723 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20150416 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20131029 Patent event code: PB09011R02I |
|
| B601 | Maintenance of original decision after re-examination before a trial | ||
| PB0601 | Maintenance of original decision after re-examination before a trial |
Comment text: Report of Result of Re-examination before a Trial Patent event code: PB06011S01D Patent event date: 20150901 |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2015101004182; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20150723 Effective date: 20170220 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20170220 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20150723 Decision date: 20170220 Appeal identifier: 2015101004182 |